# Shukra Pharma (NSE: SHUKRAPHAR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SHUKRAPHAR · Pivot · prices to 22 Oct 2026

Shukra Pharma (NSE: SHUKRAPHAR) closed at ₹63.62 on 22 Oct 2026, down 7.18% on the day. With a market capitalisation of ₹2,797 Cr, it ranks 999th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 127.2× trailing earnings, against a return on equity of 15.2% in FY25. Its 52-week range is ₹40.06 (14 Aug 2026) to ₹75.40 (6 Oct 2026); the last close is 15.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹6 Cr (−52.4% year on year) and net profit −₹2 Cr (−131.9%), on a consolidated basis. Promoters held 51.15% of the company as of 3 Aug 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹63.62 |
| Market cap | ₹2,797 Cr |
| P/E (trailing) | 127.2 |
| ROE | 15.2% (FY25) |
| ROCE | 20.0% (FY25) |
| Debt to equity | 0.07 |
| 52-week high | ₹75.40 (6 Oct 2026) |
| 52-week low | ₹40.06 (14 Aug 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹6 Cr | −52.4% | −₹2 Cr | −131.9% | −₹0.04 |
| Q3 FY26 | ₹39 Cr | +269.8% | ₹20 Cr | +544.3% | ₹0.47 |
| Q2 FY26 | ₹6 Cr | — | ₹2 Cr | — | ₹0.05 |
| Q1 FY26 | ₹5 Cr | — | ₹1 Cr | — | ₹0.02 |
| Q4 FY25 | ₹13 Cr | — | ₹5 Cr | — | ₹0.12 |
| Q3 FY25 | ₹11 Cr | — | ₹3 Cr | — | ₹0.72 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹33 Cr | ₹10 Cr |
| FY24 | ₹75 Cr | ₹19 Cr |
| FY23 | ₹59 Cr | ₹4 Cr |
| FY22 | ₹20 Cr | ₹1 Cr |
| FY21 | ₹11 Cr | ₹0 Cr |
| FY20 | ₹12 Cr | ₹0 Cr |

## Shareholding (3 Aug 2026)

- Promoters: 51.15%
- Foreign institutions: 0.00%
- Domestic institutions: 0.11%
- Non-institutions: 48.73%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Solara Active Pharma Sciences](https://app.pivotnow.in/stock/SOLARA) | ₹650.75 | ₹3,140 Cr | — | — |
| [Ind-Swift Laboratories](https://app.pivotnow.in/stock/INDSWFTLAB) | ₹347.05 | ₹3,018 Cr | 71.6 | — |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹265.45 | ₹2,972 Cr | 17.6 | — |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |
| [Hikal](https://app.pivotnow.in/stock/HIKAL) | ₹210.01 | ₹2,589 Cr | — | — |
| [Dr Agarwals Eye Hospital](https://app.pivotnow.in/stock/DRAGARWQ) | ₹5,025.00 | ₹2,428 Cr | — | — |

## Questions and answers

### What is the share price of Shukra Pharma today?

Shukra Pharma (NSE: SHUKRAPHAR) last closed at ₹63.62 on 22 Oct 2026. Its 52-week high is ₹75.40 and its 52-week low is ₹40.06.

### What is the market cap of Shukra Pharma?

Shukra Pharma's market capitalisation is ₹2,797 Cr (₹2,797 Cr) at the 22 Oct 2026 close, ranking 999th among the NSE companies Pivot tracks.

### What is the P/E ratio of Shukra Pharma?

Shukra Pharma trades at a trailing P/E of 127.2.

### What is the ROE and ROCE of Shukra Pharma?

Return on equity was 15.2% in FY25 and return on capital employed was 20.0% in FY25 (standalone figures).

### Is Shukra Pharma a debt-free company?

No. Shukra Pharma's debt-to-equity ratio was 0.07 in FY25, with total debt of ₹3 Cr.

### What were Shukra Pharma's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Shukra Pharma reported revenue of ₹6 Cr, −52.4% year on year, and net profit of −₹2 Cr, −131.9% year on year.

### What is the shareholding pattern of Shukra Pharma?

As of 3 Aug 2026: promoters 51.15%, foreign institutions 0.00%, domestic institutions 0.11%, non-institutions 48.73%.

### Who are Shukra Pharma's competitors?

The listed Pharma & Healthcare companies closest to Shukra Pharma by market cap are Solara Active Pharma Sciences, Ind-Swift Laboratories, Advanced Enzyme Technologies, Dishman Pharma, Hikal and Dr Agarwals Eye Hospital.

### Is Shukra Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Shukra Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SHUKRAPHAR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.